Search research articles
Contact Us
Filters
Showing results (381-390 of 431) with videos related to
Page
of 44
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
June 3, 2019
Tool inhibitors and assays to interrogate the biology of the TRAF2 and NCK interacting kinase
Jon Read, Iain T Collie, Michelle Nguyen-McCarty, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
December 18, 2008
The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine
Sean M Smith, Jason M Uslaner, Lihang Yao, et al.
Neuropharmacology
|
December 1, 2015
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects
Robert W Gould, Michael T Nedelcovych, Xuewen Gong, et al.
Molecular Brain
|
May 6, 2020
Axl receptor tyrosine kinase is a regulator of apolipoprotein E
Wenchen Zhao, Jianjia Fan, Iva Kulic, et al.
Molecular Psychiatry
|
January 25, 2014
DISC1 as a genetic risk factor for schizophrenia and related major mental illness: response to Sullivan
D J Porteous, P A Thomson, J K Millar, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 1, 2016
Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition
Michael R Wood, Meredith J Noetzel, James C Tarr, et al.
Molecular Psychiatry
|
September 27, 2007
Evidence that many of the DISC1 isoforms in C57BL/6J mice are also expressed in 129S6/SvEv mice
K Ishizuka, J Chen, S Taya, et al.
Nature Medicine
|
May 10, 2016
A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus
Ming Li, Andrew E Jaffe, Richard E Straub, et al.
Cancer Cell
|
November 5, 2019
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Huiying Han, Atul D Jain, Mihai I Truica, et al.
AIDS (London, England)
|
September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection
Pedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Page
of 44
Search research articles
Search
Showing results (381-390 of 431) with videos related to
Sort By:
Page
of 44
Bioorganic & Medicinal Chemistry Letters
|
June 3, 2019
Tool inhibitors and assays to interrogate the biology of the TRAF2 and NCK interacting kinase
Jon Read, Iain T Collie, Michelle Nguyen-McCarty, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
December 18, 2008
The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine
Sean M Smith, Jason M Uslaner, Lihang Yao, et al.
Neuropharmacology
|
December 1, 2015
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects
Robert W Gould, Michael T Nedelcovych, Xuewen Gong, et al.
Molecular Brain
|
May 6, 2020
Axl receptor tyrosine kinase is a regulator of apolipoprotein E
Wenchen Zhao, Jianjia Fan, Iva Kulic, et al.
Molecular Psychiatry
|
January 25, 2014
DISC1 as a genetic risk factor for schizophrenia and related major mental illness: response to Sullivan
D J Porteous, P A Thomson, J K Millar, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 1, 2016
Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition
Michael R Wood, Meredith J Noetzel, James C Tarr, et al.
Molecular Psychiatry
|
September 27, 2007
Evidence that many of the DISC1 isoforms in C57BL/6J mice are also expressed in 129S6/SvEv mice
K Ishizuka, J Chen, S Taya, et al.
Nature Medicine
|
May 10, 2016
A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus
Ming Li, Andrew E Jaffe, Richard E Straub, et al.
Cancer Cell
|
November 5, 2019
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Huiying Han, Atul D Jain, Mihai I Truica, et al.
AIDS (London, England)
|
September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection
Pedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Page
of 44